One Nucleus’ On Helix Conference 2023, provided insight into the current climate for Biotech companies, including the international outlook, and what to expect in the future. The past few years have been tough for the international Biotech market, with funding, Brexit, new regulations, trade agreements and supply chain issues. Additionally, valuations have fallen and consequently […]
YOUNG biotech companies need “patient investors” with “deep pockets” to weather today’s financial storms, the head of Novo Holdings Seed Investments has told the Optimum Perspectives podcast. In an in-depth interview, Søren Møller said fledgling firms should accept it might be some time before investor confidence returns to the sector – and they need to […]
LET’S play a word association game. AI. Healthcare. Are you thinking what I’m thinking? If so, you‘re thinking about drug discovery. It is a very hot topic in pharma right now. Billions are being poured into efforts to use artificial intelligence (AI) to spot new drugs. And for good reason. ‘Traditional’ drug discovery methods are […]
Calliditas is one of European biopharma’s big success stories, bringing a rare disease drug to market and commercializing it using its own sales force. Richard Staines from Optimum Strategic Communications spoke with CEO Renée Aguiar-Lucander who outlined the challenges the company has faced on its journey. Lengthy experience as a life science investor has helped […]
Scarlet Therapeutics, a leader in red blood cell-based therapeutics (tRBCs), has launched with seed funding from Science Creates Ventures and Meltwind to further develop its platform. Born out of more than a decade of research at the University of Bristol and spearheaded by Professors Ashley Toye and Jan Frayne, with CEO Alistair Irvine at the […]
